Modified Citrus Pectin to Treat Cancer - Quick Reference Sheet
evipedia.ai
← Back

Modified Citrus Pectin to Treat Cancer

Created on 09/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A citrus-peel fibre cut into short, partly absorbable pieces and sold as a supplement for people with cancer. The strongest human signal: in men whose prostate marker was rising after local treatment, its climb slowed. Those studies had no comparison group and were funded by the seller. The safety record is unusually clean; the upside is unproven rather than disproven. (Full Review)

Protocol

Standard dose
4.8 g PectaSol-C three times daily
Totalling 14.4 g; the regimen used across the five-centre Israeli phase II trials and closest to a de facto standard.
Alternative powder regimen
5 g powder three times daily
In water or juice at eight-hour intervals; the dose used in the German advanced-solid-tumour pilot.
Best time of day
Empty stomach, about one hour before meals
Limits food-matrix binding and keeps the four-hour medication separation practical across a day.
Time to effect
PSA doubling time
6 to 18 months
The marker endpoint takes months, not weeks; response assessed at six months, imaging at six and eighteen. No meaningful earlier read-out exists.
Disease stabilisation
8 weeks
Two four-week cycles before evaluation in the advanced-solid-tumour pilot; stable disease held beyond 24 weeks in a minority.
Heavy-metal excretion
24 hours to 6 days
Urinary arsenic rose within 24 hours; cadmium and lead by day six, in healthy adults.

Benefits

Contraindications
  • Prior anaphylaxis or systemic reaction to cashew, pistachio or pectin-containing foods
  • Advanced chronic kidney disease (eGFR below 30 mL/min/1.73 m²)
  • Known or suspected bowel obstruction, stricture, or Crohn's disease with stenosis
  • Substitution for indicated salvage radiotherapy or hormone therapy in Gleason 8 to 10 disease with PSA doubling time under 3 months
  • Pregnancy and lactation
    •
Key Interactions
  • Cardiac glycosides (digoxin)
  • Statins (lovastatin, simvastatin, atorvastatin)
  • Levothyroxine, tetracyclines and fluoroquinolones
  • Oral chemotherapy and androgen-receptor agents (abiraterone, enzalutamide, capecitabine)
  • Fat-soluble vitamins and carotenoids (vitamins A, D, E, K, beta-carotene)
  • Warfarin
  • Over-the-counter absorption-sensitive products (antacids, kaolin-pectin antidiarrhoeals, oral iron)
  • Other bulking supplements (psyllium, glucomannan, guar gum)
  • Other galectin-3-directed agents (belapectin, GB1211)
    •

Risk & Side Effects

  • Low: Gastrointestinal intolerance; allergic reaction in cashew- or pistachio-sensitised people; reduced absorption of co-administered oral drugs; deferred effective therapy on the strength of a surrogate marker
  • Speculative: Gut dysbiosis and loss of butyrate production; mobilisation of stored heavy metals without adequate clearance

Monitoring

Marker Target Why
PSA Post-prostatectomy: under 0.2 ng/mL. Post-radiation: under nadir + 2 ng/mL Primary response signal
PSA doubling time Above 9 months (good-risk band); lengthening from baseline is the operative target The endpoint the human trials actually moved
Serum galectin-3 Under 14 ng/mL; where no target is agreed for oncology use, track change from the individual's own baseline Putative target engagement
hs-CRP Under 1.0 mg/L Inflammatory load that tracks with tumour activity
eGFR and creatinine eGFR above 60 mL/min/1.73 m²; creatinine within the individual's own stable range Clearance of absorbed fragments and mobilised metals
Ferritin and serum zinc Ferritin 50–150 ng/mL; zinc 90–120 µg/dL Detects any real-world mineral binding
Testosterone Above 150 ng/dL (the trial entry threshold) Confirms PSA changes are not driven by hormonal suppression

Cadence: PSA monthly for the first six months, then every one to three months; kidney function and blood counts every three to six months; imaging at six and eighteen months, or sooner if the marker rises by a quarter or more from baseline without the doubling time lengthening.

Qualitative Assessment

  • Bowel pattern, bloating and flatulence, as the dose-limiting experience in practice
  • Energy and fatigue, the domain in which the advanced-tumour pilot reported change
  • Appetite and weight stability
  • Pain scores where disease-related pain exists
  • Adherence: how many of the three daily doses were actually taken
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.